Last reviewed · How we verify
Supportive care+Tacrolimus+Ripertamab
Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression.
Ripertamab is a bispecific antibody that engages immune cells to target and eliminate cancer cells, combined with supportive care and tacrolimus immunosuppression. Used for Hematologic malignancies (investigational, Phase 3).
At a glance
| Generic name | Supportive care+Tacrolimus+Ripertamab |
|---|---|
| Also known as | Test group 1 |
| Sponsor | Air Force Military Medical University, China |
| Drug class | Bispecific antibody |
| Target | T-cell engager (exact targets not fully characterized in public literature) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ripertamab functions as a bispecific antibody designed to bridge T cells and tumor cells, facilitating immune-mediated killing. Tacrolimus provides immunosuppressive support to manage immune-related complications. The combination with supportive care addresses clinical management of the underlying condition being treated.
Approved indications
- Hematologic malignancies (investigational, Phase 3)
Common side effects
- Cytokine release syndrome
- Immune-related adverse events
- Infection risk (from tacrolimus immunosuppression)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: